Cartesian Therapeutics, Inc. — Director's Dealing 2024

Mar 28, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2024-01-17

Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-17	Common Stock	P	800	$0.69	Acquired	87218	Indirect
2024-02-06	Common Stock	P	800	$0.65	Acquired	88018	Indirect
2024-02-07	Common Stock	P	2400	$0.6563	Acquired	90418	Indirect
2024-03-08	Common Stock	P	4800	$0.6639	Acquired	95218	Indirect
2024-03-11	Common Stock	P	1200	$0.6541	Acquired	96418	Indirect
2024-03-12	Common Stock	P	1200	$0.6122	Acquired	97618	Indirect
2024-03-13	Common Stock	P	3200	$0.5837	Acquired	100818	Indirect
2024-03-14	Common Stock	P	2000	$0.5305	Acquired	102818	Indirect
2024-03-15	Common Stock	P	1200	$0.56	Acquired	104018	Indirect
2024-03-18	Common Stock	P	800	$0.61	Acquired	104818	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	7471625	Direct
Common Stock	33043849	Indirect

Footnotes

F1: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.65 to $0.67. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.65 to $0.68. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F3: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.65 to $0.66. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F4: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.61 to $0.62. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F5: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.58 to $0.59. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F6: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.52 to $0.54. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F7: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.